Youngquist trust discloses 7.85M Coherus (CHRS) shares in 13G
Rhea-AI Filing Summary
Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock. This represents 6.49% of the outstanding common shares, based on 120,871,013 shares outstanding as of October 31, 2025.
The trust has sole power to vote and dispose of these 7,850,800 shares. The position includes 560,000 shares underlying call options that are counted as beneficially owned because they are exercisable within 60 days. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Coherus (CHRS) is reported by the Timothy G. Youngquist 2020 Irrevocable Trust?
The trust reports beneficial ownership of 7,850,800 Coherus shares, representing 6.49% of the common stock. This percentage is based on 120,871,013 shares outstanding as of October 31, 2025, as disclosed in Coherus’ Form 10-Q.
How was the 6.49% ownership percentage in Coherus (CHRS) calculated in this Schedule 13G?
The 6.49% ownership is calculated using 7,850,800 beneficially owned shares divided by 120,871,013 Coherus common shares outstanding as of October 31, 2025. That outstanding share figure comes from Coherus’ Form 10-Q filed November 6, 2025.
Does the Coherus (CHRS) Schedule 13G include options in the reported ownership?
Yes. The reported 7,850,800 shares include 560,000 shares underlying call options. These options constitute a right to acquire Coherus common stock within 60 days, so they are counted as beneficially owned under Rule 13d-3 for percentage-of-class calculations.
Is the reported Coherus (CHRS) stake intended to influence control of the company?
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Coherus, nor in connection with any transaction having that control-related purpose or effect.